V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160015526 | 160007685 | 1.65 | 100 | Palliative (P) | 2018-01-28 | 2018-02-06 | Pemetrexed | 02 | N | AZACITIDINE | 100474742 |
| 160015527 | 160007686 | 1.62 | 100 | Palliative (P) | 2018-06-28 | 2018-07-17 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100274830 |
| 160015528 | 160007687 | 1.76 | 71.6 | 02 | 2016-05-27 | 2016-06-03 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101653921 |
| 160015529 | 160007688 | null | null | null | 2019-12-09 | 2020-01-12 | EW EuroEwing 2012 Arm B VDC | 02 | null | EURO-EWING | 100932314 |
| 160015532 | 160007689 | 1.78 | 89.6 | Curative (C) | 2016-12-15 | 2016-12-15 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | LIPOSOMAL DOXORUBICIN | 101807246 |
| 160015533 | 160007690 | 1.78 | 92 | Palliative (P) | 2019-05-18 | 2019-05-25 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101814440 |
| 160015535 | 160007691 | 1.79 | 94.8 | Palliative (P) | 2017-11-22 | 2017-12-03 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101424685 |
| 160015536 | 160007692 | 1.58 | 55.3 | Palliative (P) | 2021-07-21 | 2021-07-30 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 101364893 |
| 160015539 | 160007693 | 1.73 | 72.6 | Palliative (P) | 2019-03-19 | 2019-03-25 | Trabectedin | 02 | N | DOXORUBICIN + OLARATUMAB | 100379343 |
| 160015540 | 160007694 | 1.71 | 97 | Neo-adjuvant (N) | 2018-11-03 | 2018-11-11 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100010617 |
| 160015541 | 160007695 | 1.54 | 77.4 | null | 2018-01-07 | 2018-01-18 | Pemetrexed | 02 | N | MAP | 100909480 |
| 160015543 | 160007696 | 1.78 | 62.6 | Palliative (P) | 2019-01-06 | 2019-01-27 | Cisplatin + Pemetrexed | N | null | CISPLATIN + PEMETREXED | 100376758 |
| 160015545 | 160007697 | 1.76 | 61.9 | 03 | 2016-12-08 | 2016-12-08 | Doxorubicin + Ifosfamide | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 101403798 |
| 160015546 | 160007698 | null | null | Palliative (P) | 2016-11-25 | 2016-12-26 | Carboplatin + Etoposide IV 3 day | 02 | null | RMS 2005 TRIAL | 100846459 |
| 160015548 | 160007700 | 1.68 | 20.4 | null | 2019-09-07 | 2019-09-27 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101738382 |
| 160015550 | 160007701 | 1.78 | 68 | Curative (C) | 2018-01-14 | 2018-01-18 | Rucaparib | 02 | N | CISPLATIN + ETOPOSIDE | 101538088 |
| 160015551 | 160007702 | 1.85 | 41.4 | Curative (C) | 2014-01-12 | 2014-01-12 | Liposomal Doxorubicin (Caelyx) | N | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 101215267 |
| 160015553 | 160007703 | null | null | null | 2019-06-22 | 2019-07-19 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101523844 |
| 160015558 | 160007704 | 1.73 | 84.8 | 03 | 2016-09-06 | 2016-09-24 | Cisplatin + Pemetrexed | 01 | N | CISPLATIN + PEMETREXED | 100574912 |
| 160015559 | 160007705 | 1.8 | 78.2 | Palliative (P) | 2019-09-17 | 2019-09-21 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100215341 |
| 160015562 | 160007706 | 1.73 | 75.05 | Palliative (P) | 2017-06-07 | 2017-06-07 | Carboplatin + Paclitaxel (3 weekly) | N | null | CARBOPLATIN + PACLITAXEL | 100083636 |
| 160015563 | 160007707 | 1.8 | 70 | Palliative (P) | 2022-03-10 | 2022-03-16 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100221532 |
| 160015564 | 160007708 | 1.78 | 75.2 | Palliative (P) | 2017-02-09 | 2017-02-09 | Trial Unspecified | N | Y | TRIAL UNSPECIFIED | 100226517 |
| 160015565 | 160007709 | 1.52 | null | Palliative (P) | null | 2018-09-09 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100376838 |
| 160015567 | 160007710 | 1.67 | 72 | Disease modification (D) | 2018-11-02 | 2018-11-03 | Doxorubicin + Olaratumab | null | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 101165601 |
| 160015570 | 160007711 | 1.79 | 87 | null | 2017-05-16 | 2017-05-16 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | null | CAV | 100897573 |
| 160015572 | 160007712 | 1.74 | 66 | Neo-adjuvant (N) | 2018-02-01 | 2018-02-05 | Trial Unspecified | 99 | N | TRIAL UNSPECIFIED | 101189221 |
| 160015581 | 160007714 | 1.93 | 77 | Palliative (P) | 2018-02-10 | 2018-02-10 | VAC | 02 | N | DOXORUBICIN | 100172678 |
| 160015582 | 160007715 | 1.57 | 93.6 | Curative (C) | 2017-05-14 | 2017-05-14 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 101434428 |
| 160015590 | 160007716 | 1.74 | 80 | Palliative (P) | 2016-02-14 | 2016-03-01 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101389930 |
| 160015591 | 160007717 | 1.67 | 95.4 | 03 | 2017-06-13 | 2017-07-10 | Doxorubicin + Ifosfamide | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100232763 |
| 160015592 | 160007718 | 0 | 0 | Neo-adjuvant (N) | 2017-08-30 | 2017-08-31 | IBRUTINIB | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101399064 |
| 160015593 | 160007719 | 1.78 | 78 | Palliative (P) | 2019-01-03 | 2019-01-10 | Carboplatin + Etoposide iv&po | 02 | N | DOXORUBICIN + OLARATUMAB | 100812647 |
| 160015595 | 160007720 | 1.68 | 97.7 | Curative (C) | 2018-02-10 | 2018-02-18 | Carboplatin + Liposomal Doxorubicin | N | N | DOXORUBICIN | 100668641 |
| 160015597 | 160007721 | 1.64 | 49 | Palliative (P) | 2018-11-07 | 2018-11-07 | Liposomal Doxorubicin + Rituximab | 02 | N | IPILIMUMAB + NIVOLUMAB | 101417937 |
| 160015598 | 160007722 | 1.74 | 81.5 | Palliative (P) | 2020-04-05 | 2020-04-05 | Doxorubicin + Olaratumab | N | N | CARBOPLATIN + PACLITAXEL | 100842077 |
| 160015600 | 160007723 | 1.74 | 61 | null | 2018-09-05 | 2018-09-05 | Doxorubicin + Olaratumab | 01 | N | ENZALUTAMIDE | 101463599 |
| 160015601 | 160007724 | 1.65 | 70 | Palliative (P) | 2018-01-24 | 2018-02-13 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100749332 |
| 160015602 | 160007725 | 1.79 | 71.6 | Neo-adjuvant (N) | 2017-12-19 | 2018-01-10 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101286851 |
| 160015610 | 160007726 | 1.66 | 64 | Neo-adjuvant (N) | 2016-03-27 | 2016-03-27 | Ifosfamide | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 101394880 |
| 160015611 | 160007727 | 1.6 | 56.6 | Palliative (P) | 2017-06-21 | 2017-06-22 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 101580672 |
| 160015614 | 160007728 | 1.8 | 99.3 | Palliative (P) | 2017-01-09 | 2017-01-28 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100093550 |
| 160015615 | 160007729 | 1.8 | 65 | Palliative (P) | 2018-09-02 | 2018-09-04 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101056063 |
| 160015618 | 160007730 | 0 | 0 | Palliative (P) | 2020-04-08 | 2020-04-10 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 101108126 |
| 160015619 | 160007731 | 1.57 | 84 | Disease modification (D) | 2018-03-03 | 2018-03-04 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101077632 |
| 160015621 | 160007732 | 1.74 | 75.9 | Curative (C) | 2017-07-02 | 2017-07-02 | Liposomal Doxorubicin (Caelyx) | 02 | N | VDC | 100909411 |
| 160015623 | 160007733 | 1.78 | null | Palliative (P) | 2018-11-12 | 2018-11-12 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101534230 |
| 160015624 | 160007734 | 1.5 | 54.8 | Palliative (P) | 2019-11-27 | 2019-11-27 | Carboplatin AUC 2 - 5 | N | N | CARBOPLATIN | 100661187 |
| 160015626 | 160007735 | 1.63 | 64.9 | Palliative (P) | 2018-12-07 | 2018-12-31 | Trial Unspecified | N | N | BEP | 100794700 |
| 160015627 | 160007736 | 1.67 | 70.6 | Palliative (P) | 2018-04-12 | 2018-04-12 | DOXORUBICIN | 02 | null | DOCETAXEL | 101532400 |